IBSA USA
Brandon O'Callahan is an accomplished sales representative in the pharmaceutical industry, currently serving as an Endocrinology & Pain Specialty Sales Representative at IBSA USA since March 2023. Prior to this role, Brandon was recognized as a 2022 President’s Club Recipient while working as a Digital Health Pharmaceutical Sales Representative at Teva Pharmaceuticals from January 2022 to March 2023, where Brandon partnered with Allergists and Pulmonologists to promote CINQAIR. Earlier in their career, Brandon gained experience as a Financial Services Representative at Barnum Financial Group. Brandon holds a Bachelor of Arts degree from Providence College, completed in 2020, and furthered education at Trinity College Dublin in early 2019.
This person is not in any teams
IBSA USA
IBSA USA is the subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland. IBSA is committed to improving patient quality of life through research, innovation, and the development of effective drugs and cutting-edge technologies. IBSA USA markets two unique levothyroxine formulations in the U.S. for the treatment of hypothyroidism: Tirosint® (levothyroxine sodium) capsules and Tirosint®-SOL (levothyroxine sodium) oral solution. IBSA also markets Licart™ (diclofenac epolamine) topical system 1.3%, the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) available in the U.S. to treat acute pain due to minor strains, sprains, and contusions. IBSA is focused on the health and well-being of patients and driven by the desire to bring therapeutic alternatives to as many people as possible. IBSA Group bases its philosophy on four sustainable pillars: Person, Innovation, Quality, and Responsibility. For more information about Tirosint, Tirosint-SOL, or Licart, including Full Prescribing Information, go to each brand’s respective website.